Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2009

01-09-2009

Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series

Authors: Giuseppe Viale, Nicole Rotmensz, Patrick Maisonneuve, Enrico Orvieto, Eugenio Maiorano, Viviana Galimberti, Alberto Luini, Marco Colleoni, Aron Goldhirsch, Alan S. Coates

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Login to get access

Abstract

Whether invasive lobular carcinoma of the breast per se constitutes a prognostically favorable type has been debated. The present series comprises 301 consecutive “classic” lobular breast carcinomas seen at one institution between 1994 and 2001, compared to an equal number of invasive ductal carcinomas at the same institution during the same period, matched for year of surgery, age, menopausal status, primary tumor size, nodal involvement, hormone receptor status and where possible histological grade. Despite matching, the lobular carcinomas were more frequently multifocal, had more involved nodes, lower grade and lower proliferative fraction. There was no significant difference in disease-free or overall survival, locoregional relapse or time to distant metastasis between the lobular and ductal groups overall or within any examined subset, though the lobular group showed a trend to earlier appearance of contralateral breast cancer. Classical lobular histology is not an independent factor in the prognosis of early breast cancer.
Literature
1.
go back to reference Fisher ER, Gregorio RM, Fisher B et al (1975) The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no 4). Cancer 36:1–85. doi :10.1002/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4PubMedCrossRef Fisher ER, Gregorio RM, Fisher B et al (1975) The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no 4). Cancer 36:1–85. doi :10.1002/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4PubMedCrossRef
2.
go back to reference Ellis IO, Galea M, Broughton N et al (1992) Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20:479–489PubMed Ellis IO, Galea M, Broughton N et al (1992) Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20:479–489PubMed
4.
go back to reference du Toit RS, Locker AP, Ellis IO et al (1991) An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 17:251–257PubMed du Toit RS, Locker AP, Ellis IO et al (1991) An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 17:251–257PubMed
6.
go back to reference Dian D, Herold H, Mylonas I et al (2008) Survival analysis between patients with invasive ductal and invasive lobular breast cancer. Arch Gynecol Obstet. doi:10.1007/s00404-008-0662-z Dian D, Herold H, Mylonas I et al (2008) Survival analysis between patients with invasive ductal and invasive lobular breast cancer. Arch Gynecol Obstet. doi:10.​1007/​s00404-008-0662-z
7.
go back to reference Toikkanen S, Pylkkanen L, Joensuu H (1997) Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 76:1234–1240PubMed Toikkanen S, Pylkkanen L, Joensuu H (1997) Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 76:1234–1240PubMed
8.
go back to reference Silverstein MJ, Lewinsky BS, Waisman JR et al (1994) Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 73:1673–1677. doi :10.1002/1097-0142(19940315)73:6<1673::AID-CNCR2820730620>3.0.CO;2-BPubMedCrossRef Silverstein MJ, Lewinsky BS, Waisman JR et al (1994) Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 73:1673–1677. doi :10.1002/1097-0142(19940315)73:6<1673::AID-CNCR2820730620>3.0.CO;2-BPubMedCrossRef
9.
go back to reference Casolo P, Raspadori A, Drei B et al (1997) Natural history of breast cancer: lobular carcinoma versus ductal carcinoma in our experience. Ann Ital Chir 68:43–47PubMed Casolo P, Raspadori A, Drei B et al (1997) Natural history of breast cancer: lobular carcinoma versus ductal carcinoma in our experience. Ann Ital Chir 68:43–47PubMed
10.
go back to reference Fondrinier E, Guerin O, Lorimier G (1997) A comparative study of metastatic patterns of ductal and lobular carcinoma of the breast from two matched series (376 patients). Bull Cancer 84:1101–1107PubMed Fondrinier E, Guerin O, Lorimier G (1997) A comparative study of metastatic patterns of ductal and lobular carcinoma of the breast from two matched series (376 patients). Bull Cancer 84:1101–1107PubMed
13.
go back to reference Arpino G, Bardou VJ, Clark GM et al (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:R149–R156. doi:10.1186/bcr767 PubMedCrossRef Arpino G, Bardou VJ, Clark GM et al (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:R149–R156. doi:10.​1186/​bcr767 PubMedCrossRef
14.
go back to reference Santiago RJ, Harris EE, Qin L et al (2005) Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience. Cancer 103:2447–2454. doi:10.1002/cncr.21071 PubMedCrossRef Santiago RJ, Harris EE, Qin L et al (2005) Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience. Cancer 103:2447–2454. doi:10.​1002/​cncr.​21071 PubMedCrossRef
15.
go back to reference Gonzalez-Angulo AM, Sahin A, Krishnamurthy S et al (2006) Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer 7:396–400PubMedCrossRef Gonzalez-Angulo AM, Sahin A, Krishnamurthy S et al (2006) Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer 7:396–400PubMedCrossRef
16.
go back to reference Tubiana-Hulin M, Stevens D, Lasry S et al (2006) Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 17:1228–1233. doi:10.1093/annonc/mdl114 PubMedCrossRef Tubiana-Hulin M, Stevens D, Lasry S et al (2006) Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 17:1228–1233. doi:10.​1093/​annonc/​mdl114 PubMedCrossRef
17.
go back to reference Ni MJ, Curran C, Hennessy E et al (2008) Prospective matched-pair comparison of outcome after treatment for lobular and ductal breast carcinoma. Br J Surg. doi:10.1002/bjs.6042 Ni MJ, Curran C, Hennessy E et al (2008) Prospective matched-pair comparison of outcome after treatment for lobular and ductal breast carcinoma. Br J Surg. doi:10.​1002/​bjs.​6042
20.
go back to reference Pestalozzi BC, Zahrieh D, Mallon E et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. J Clin Oncol. doi:10.1200/JCO.2007.14.9336 Pestalozzi BC, Zahrieh D, Mallon E et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. J Clin Oncol. doi:10.​1200/​JCO.​2007.​14.​9336
23.
go back to reference Borst MJ, Ingold JA (1993) Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114:637–641PubMed Borst MJ, Ingold JA (1993) Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114:637–641PubMed
24.
go back to reference Orvieto E, Maiorano E, Bottiglieri L et al (2008) Clinico-pathological characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer (in press) Orvieto E, Maiorano E, Bottiglieri L et al (2008) Clinico-pathological characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer (in press)
26.
go back to reference Thor AD, Liu S, Moore DH et al (1999) Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17:470–477PubMed Thor AD, Liu S, Moore DH et al (1999) Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17:470–477PubMed
Metadata
Title
Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series
Authors
Giuseppe Viale
Nicole Rotmensz
Patrick Maisonneuve
Enrico Orvieto
Eugenio Maiorano
Viviana Galimberti
Alberto Luini
Marco Colleoni
Aron Goldhirsch
Alan S. Coates
Publication date
01-09-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0112-4

Other articles of this Issue 1/2009

Breast Cancer Research and Treatment 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine